Skip to Main Content

Paper Details

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
J Immunother Cancer
29
2022
Author NameAffiliation
Shubham PantUniversity of Texas MD Anderson Cancer Center
Johann S de BonoThe Institute of Cancer Research
Johann S de BonoRoyal Marsden Hospital NHS Trust
  • 1 - 3

Datasets

Release 1.2